The Bull Rankings scorecard — our quality-growth score is 53.7 / 100, built from three pillars scored 0–100: Quality 62, Growth 60, Value 41 (valuation is judged against sector peers). At today's price, our reverse-DCF read says the market is implicitly betting on free-cash-flow growth of about 14% a year next year, fading to 3% a year by year ten — a gauge of how much optimism is already in the stock.
The thesis
Danaher’s numbers in the quarter ended 2026-06-26 don’t scream “cheap,” but they don’t scream “overpriced” either. The stock trades at 38.5 times trailing earnings while the company prints a 15.9% profit margin and generates $5.5 billion in free cash flow. That cash engine is the real story: it’s what allows the company to raise its dividend even as the market questions the sustainability of a 4.6% revenue increase. Our quality-growth score of 53.7 puts Quality at 62 and Growth at 60, the strongest pillars, while Value lags at 41. The market is paying up for durability, not a discount.
What the business actually is
Danaher sells tools that keep the life-science ecosystem running. In Biotechnology, it provides cell culture media, chromatography resins, and single-use hardware used to manufacture biologics. Life Sciences delivers filtration technologies and process liquids for drug development. Diagnostics offers instruments and consumables for clinical labs. Each segment sells consumables and capital equipment to pharma, biotech, and academic labs, locking in recurring revenue streams that compound when new drugs enter the pipeline.
Why it can (or can't) keep compounding
The moat is built into the product mix. Consumables like cell culture media and chromatography resins are consumed in every batch, creating sticky, high-margin revenue that competitors can’t dislodge without re-qualifying entire manufacturing lines. The Biotechnology segment’s services—cell line development, aseptic fill-finish—add another layer of integration that raises switching costs. Our model’s “Raising its dividend” signal points to management’s confidence in that cash flow. Yet the 7.6% ROE is modest, one reason the Quality pillar sits at 62 rather than higher.
The valuation question
The reverse-DCF tells the clearest story. At $215.68, the model implies Danaher must grow free cash flow at roughly 14% a year (in year one, slowing to 3% a year by year ten) to justify today’s price. That’s more than triple the 4.6% revenue growth reported in the quarter ended 2026-06-26. The math assumes either accelerating end-market demand, pricing power beyond current levels, or both. The PEG ratio of 1.41 reinforces the point: the market is not rewarding value, it’s rewarding the belief that growth will reaccelerate. Until the 14% FCF growth shows up in the reported numbers, the optimism is priced in.
The bear case
The weakest pillar—Value at 41—is the simplest bear argument. The stock’s 38.5 P/E sits well above the sector median, and the 15.9% margin, while solid, isn’t expanding. If revenue growth slips below 4% or margins compress toward 14%, the multiple will compress faster than the dividend can grow. The bear points to the 0.53 debt-to-equity ratio and asks why a company with such strong cash flow needs leverage at all. Until the growth gap closes, the valuation risk remains.
What would change our mind
Two numbers would flip the thesis. First, if revenue growth accelerates to 6% or more in the next reported quarter, the implied 14% FCF growth becomes plausible instead of heroic. Second, if the ROE climbs above 9%, our Quality pillar would strengthen, signaling that capital is being deployed more efficiently. Either shift would reduce the reliance on future optimism and reward the current multiple. Until then, the market is betting on a comeback, not a bargain.